Meeting
2019 ASCO Annual Meeting
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
Authors
Alessandro Russo
Medical Oncology Unit-A.O. Papardo, Messina and Department of Human Pathology University of Messina, Messina, Italy
Alessandro Russo , Tindara Franchina , Giuseppina Ricciardi , Alessandra Battaglia , Silvia Schifano , Maurizio Schifilliti , Antonino Scimone , Giuseppe Toscano , Mariangela Zanghì , Vincenzo Adamo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Inflammatory Signatures
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2596)
DOI
10.1200/JCO.2019.37.15_suppl.2596
Abstract #
2596
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong
Poster
2019 ASCO Annual Meeting
Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
First Author: Bassel Nazha
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2022 ASCO Annual Meeting
Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
First Author: Jillian Moran